HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan PLC

www.allergan.com

Latest From Allergan PLC

Pharma Enforcement Remains 'Priority Area' In FTC's 2021 Budget Request

US Federal Trade Commission has mainly focused in pay-for-delay cases over the past decade, but pricing strategies are an emerging area of attention; industry is paying close attention to potential enforcement in biosimilar market.

Enforcement Legal Issues

Finance Watch: Biopharma Stocks See Big Post-IPO Jumps

Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.

Financing Business Strategies

Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine

Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.

Clinical Trials Neurology

Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings

Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.

Sales & Earnings Launches
See All

Company Information

UsernamePublicRestriction

Register